BioMarin Seeks Full FDA Approval For VOXZOGO In Achondroplasia
BioMarin (BMRN) said the FDA accepted its supplemental NDA for VOXZOGO (vosoritide) to seek full approval for children with achondroplasia. The FDA set a PDUFA action date of Feb. 28, 2027. The filing relies on data from three ongoing studies measuring adult height and other growth outcomes. BMRN shares were $59.19, up 0.11% on the day.
How this was made
The 30-second read
Why it matters
A regulatory acceptance and defined PDUFA date reduce uncertainty versus an open-ended timeline, but the key decision remains pending.
Market read
Traders can use the PDUFA date and acceptance milestone to manage regulatory-event risk and position sizing into future FDA updates.
What to watch
The article does not specify endpoint results or any FDA feedback; future FDA communications and the robustness of long-term data will likely drive the next repricing.
Background
VOXZOGO (vosoritide) received accelerated approval in 2021 and the sNDA is intended to satisfy postmarketing requirements for full approval.
Ticker impact
BioMarin said the FDA accepted its sNDA for VOXZOGO to convert from accelerated to full approval, with a PDUFA action date of Feb. 28, 2027.
Moderately positive bias over the next weeks as traders price in higher odds of full approval, with volatility around future FDA communications and study updates.
The article discloses a concrete regulatory step (FDA acceptance) and a specific PDUFA target date, but it does not provide new efficacy/safety results beyond referencing ongoing studies.
Market effects
Supports sentiment for rare-disease biotech regulatory pathways, especially FGFR3/achondroplasia treatment narratives.
Primarily US-focused regulatory catalyst for a US-listed biotech.
Could influence global expectations for achondroplasia treatment approvals and payer discussions if full approval is granted.
Counterpoint
Acceptance does not guarantee approval; traders may fade the move if FDA requests additional analyses or if long-term endpoints face scrutiny.
Key entities
- companyBioMarin Pharmaceutical Inc.
Sponsor of VOXZOGO and filer of the supplemental NDA for full FDA approval in achondroplasia.
- productVOXZOGO (vosoritide)
Achondroplasia therapy seeking conversion from accelerated to full approval based on long-term evidence.
- regulatorU.S. FDA
Accepted the sNDA and set a PDUFA target action date of Feb. 28, 2027.
